LOS ANGELES, CA — March 15, 2026 — Business Exits, a mergers and acquisitions advisory firm focused on lower middle-market and middle-market businesses, today announced that it advised on the successful sale of a hormone therapy platform in a transaction valued at $130 million.
The names of the seller and buyer remain confidential under the terms of the transaction. The acquiring party is a private equity-backed healthcare investor, and the seller retained equity to support the company’s next phase of growth.
Business Exits served as lead advisor to the seller throughout the process, including positioning, buyer outreach, negotiation support, diligence coordination, and transaction structuring.
Given the nature of the healthcare sector, the deal required close coordination across legal, regulatory, financial, and operational workstreams. Business Exits worked with both sides and their advisors to address regulatory complexity, optimize structure, and maintain momentum through confirmatory diligence and final closing steps.
In support of diligence, Business Exits also helped organize and translate operating data into decision-ready reporting, allowing the buyer and lender groups to evaluate performance trends, quality of earnings, and growth assumptions with greater precision.
“This transaction reflects what can happen when strong operators and disciplined investors align around long-term value creation,” said a spokesperson for Business Exits. “We’re proud to have helped both parties navigate a complex process and reach a successful outcome.”
The post-closing partnership is designed to accelerate expansion while preserving leadership continuity and strategic focus.
About Business Exits
Business Exits is an M&A advisory firm that helps founders and owners prepare, position, and execute successful business sales and recapitalizations across multiple industries.
Media Contact
Business Exits
[email protected]
https://businessexits.com/